Evidence map›Paper›PMID 38676497›Full record

ArticleCombinatorial chemistry & high throughput screening2025

Uncovering the Role of Anmeidan against Atherosclerosis from Integrated Network Pharmacology and Pharmacological Experiments.

Yuting Zheng, Jianxiang Wang, Chengcheng Pan, Jihong Song, Xingyue Li, Wenjing Ta, Wen Lu

Abstract read
PubMed Publisher
In one paragraph

Article in Combinatorial chemistry & high throughput screening, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yuting ZhengSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, China.
Jianxiang WangSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, China.
Chengcheng PanSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, China.
Jihong SongSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, China.
Xingyue LiSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, China.
Wenjing TaSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, China.
Wen LuSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, China.
Xi'an Jiaotong University · CN

Funding

Key Research and Development Program of Shaanxi 2024SFYBXM-486
6 · The paper itself

Abstract

backgroundAtherosclerosis (AS) is the leading cause of mortality in elderly individuals worldwide. Anmeidan (AMD) is a Traditional Chinese Medicine (TCM) formula composed of many herbs, many of which have been accepted for treating AS. This study aimed to explore whether AMD can inhibit the progress of AS and its possible mechanism.

methodsApoE

resultsIn ApoE

conclusionThis study confirmed that AMD could treat AS by regulating lipid metabolism and preliminarily explored the related mechanism. These findings provide new ideas for the treatment of AS with TCM.

Indexed as

AtherosclerosisDrugs, Chinese HerbalNetwork PharmacologyAnimalsApolipoproteins EDisease Models, AnimalHumansLipid MetabolismMaleMiceMice, Inbred C57BLMice, KnockoutApolipoproteins EDrugs, Chinese HerbalAnmeidanatherosclerosischolesterol.LC-MS/MSlipid metabolismnetwork pharmacology

Identifiers

PMID38676497
OpenAlexW4395695427

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.